Drugs / SCTB39-1
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07594028 | May 2026 → May 2029 expected | cancer | Sinocelltech Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07050641 | Jun 2025 → Jun 2028 expected | cancer | Sinocelltech Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SCTB39-1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07050641 ↗ |
| Route | Intravenous | “SCTB39-1, IV” NCT07050641 ↗ |